Beleggen.nl Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

Mooi instap moment Dendreon

1.743 Posts
Pagina: «« 1 ... 21 22 23 24 25 ... 88 »» | Laatste | Omlaag ↓
  1. jip banaan! 21 februari 2007 00:04
    quote:

    crackedtooth schreef:

    [quote=jip banaan!]
    [quote=tonpa]
    Tralalala $ 5,08 blijven zitten wordt beloond.
    [/quote]
    ben ondertussen ook royaal beloond, maar wanneer verkopen? (ik vind verkopen het moeilijkste van beleggen)
    groet jip!
    [/quote]

    of vlak voor FDA beslissing verkopen of de belissing uitzitten

    twee mogelijkheden:

    goedkeuring zonder panel -> dan heb je dikke winst

    Meest waarschijnlijke is panel, die word aangekodigd ik geloof een week of twee vantevoren, je zou dan voor een evt panelbeslissing een deel of alles kunnen verkopen als je twijfel hebt of risico wilt beperken
    dank crack voor reactie! banaantje vanjip!
  2. [verwijderd] 21 februari 2007 13:29
    Zonet van Inverstvillager gehaald: een stukje van ene croumagnon :

    Re: Why it is "different this time"

    <<we are up currently on "no" news.....it is accumulation...steady drumbeat....>>

    You got that right Chuck, and this is what makes me think that the hold the shorts have had on this stock will soon vaporize. This is unprecedented with DNDN for over three years now and the volume as well as the demand has been persistent for a while. I get the feeling that some big players on wall-street are finally realizing what many of us on this message board have known for a while. What was amazing to me today is how easily we sliced through the $5 barrier even though UBS and all the accompanying crooks tried to put up a huge fight there. Once we are solidly into the $5 territory, we will become a momentum play and you will see many funds and institutions jump on the bandwagon...

    I am now of the opinion that we will cross $7 well before the end of March when it is expected that the advisory committee meets to review Provenge. As for that review, after the NIH conference last week when we realized that Provenge is the poster child of the FDA, the NIH, and the academics, I am now of the opinion that the advisory committee will recommend approval in force. Why wouldn't they? Provenge has demonstrated a sizable survival advantage (more than 3 fold higher at 3 years) and this was done with minimal and transient side-effects (slight fever and chills lasting one or two days). The survival advantage is much larger than what chemo offers and Provenge does not have the nasty side-effects that accompany chemo... So I ask once again, why wouldn't the advisory committee recommend Provenge with flying colors? There is not a single reason and they will recommend approval overwhelmingly...

    The recent upside is nice but it is nothing compared to what lays ahead of us and I think the greatest danger facing DNDN investors is selling too early because they have been brau beaten into believing that a slight pps rise is all we can expect. This is rubbish and I have to agree with skcotswonki that $1,000 for a pps down the line is not out of the realm of possibilities. We know that the AIPC market revenues should exceed $1 Billion per year but this is simply the start. After AIPC approval we will get ADPC approval and/or off-label use and that market is 5 times larger, thus giving DNDN sales in excess of $5 Billion per year. From there we move to neuvenge and breast cancer, then to colon, kidney, lungs, etc... Basically DNDN will become the premier company for cancer immunotherapy "vaccines" and I can easily see the sales moving past $10 billion per year in a few short years. Now take a multiple of 5 times sales for a market cap and you can start to imagine DNDN heading past $50 billion in its market cap and becoming the next AMGN or DNA or the likes... Am I dreaming? Perhaps but those dreams are based on real facts that can be checked by anyone who will take the time and the effort to look at the data and consider the huge market potential that the cassette immunotherapy platform offers in the way of providing "vaccines" that allow the patients to fight and defeat cancer effectively...

    This is only the beginning folks... Just buy and hold, and hang on for one of the best rides that this market has ever offered... In the process, try to disregard the slight pullbacks that may be generated along the way by some of the hedgie crooks that feed off wall-street... These pullbacks represent their last hurrays and will be slight and short-lived... Stay long and strong, and focus on the bright future that we will all have if we simply resist the temptation of selling too early...
  3. [verwijderd] 21 februari 2007 17:47
    quote:

    crackedtooth schreef:

    [quote=tonpa]
    Sterke opening!
    [/quote]

    volume 1,8 miljoen en 3300 optie contracten
    erg hoog in 1 uur

    Zou je kunnen en willen uitleggen wat je met die optiecontracten bedoelt?
    En is deze terugval in verband hiermede te verklaren? Of gewoon winstnemen?
  4. [verwijderd] 21 februari 2007 18:13
    quote:

    crackedtooth schreef:

    25.000 optie volume???!!????
    geeft mijn broker aan

    dat is 2,5mln aandelen!!
    Kun je mij vertellen, of zij, die die opties bezitten, zullen trachten de koers te drukken of juist omhoog te krijgen?
  5. [verwijderd] 21 februari 2007 19:16
    quote:

    tonpa schreef:

    [quote=crackedtooth]
    25.000 optie volume???!!????
    geeft mijn broker aan

    dat is 2,5mln aandelen!!
    [/quote]
    Kun je mij vertellen, of zij, die die opties bezitten, zullen trachten de koers te drukken of juist omhoog te krijgen?
    niet zeker
    kan ook optie spread trade zijn
  6. [verwijderd] 21 februari 2007 20:25
    quote:

    Striker_ schreef:

    maar wie schrijft er zoveel calls?
    en wie koopt er zoveel calls?
    dat is speculeren
    kan een short of long zijn... of kan een optietrader zijn
    speculatie op ivillage is dat het een bullish spread it of een accumulatiestrategie

    maar zullen we niet weten
    maar activiteit is er zeker
  7. [verwijderd] 28 februari 2007 15:11
    quote:

    snor13854 schreef:

    Met zoveel shorts komt het met de koers van DNDN wel goed.
    Een of meer grote partijen,die nog wat willen trekken.
    RB
    denk je dat er via opties of offshore al aan coveren word gewerkt?
  8. [verwijderd] 28 februari 2007 15:19
    Rond deze koers dekken zij zich in.
    Anders een te groot risico dat het wordt opgepikt,voor een plotselinge stijging.
    Maar het blijft onzeker,tot waar die snoeshanen de koers willen hebben.

    RB
1.743 Posts
Pagina: «« 1 ... 21 22 23 24 25 ... 88 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.496
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.651
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.645
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.751
Aedifica 3 916
Aegon 3.258 322.834
AFC Ajax 538 7.088
Affimed NV 2 6.296
ageas 5.844 109.892
Agfa-Gevaert 14 2.050
Ahold 3.538 74.336
Air France - KLM 1.025 35.043
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.823
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.180
AMG 971 133.337
AMS 3 73
Amsterdam Commodities 305 6.689
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.998
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.776
Arcelor Mittal 2.033 320.709
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.300
Aroundtown SA 1 219
Arrowhead Research 5 9.739
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.097
ASML 1.766 107.192
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.667
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392